Genomic epidemiology of global carbapenemase-producing Escherichia coli, 2015–2017
| dc.contributor.author | Peirano, Gisele | |
| dc.contributor.author | Chen, Liang | |
| dc.contributor.author | Nobrega, Diego | |
| dc.contributor.author | Finn, Thomas J. | |
| dc.date.accessioned | 2023-06-08T05:12:28Z | |
| dc.date.available | 2023-06-08T05:12:28Z | |
| dc.date.issued | 2022-05 | |
| dc.description.abstract | We describe the global molecular epidemiology of 229 carbapenemase-producing Escherichia coli in 36 countries during 2015–2017. Common carbapenemases were oxacillinase (OXA) 181 (23%), New Delhi metallo-β-lactamase (NDM) 5 (20%), OXA-48 (17%), Klebsiella pneumoniae carbapenemase 2 (15%), and NDM-1 (10%). We identified 5 dominant sequence types (STs); 4 were global (ST410, ST131, ST167, and ST405), and 1 (ST1284) was limited to Turkey. OXA-181 was frequent in Jordan (because of the ST410-B4/H24RxC subclade) and Turkey (because of ST1284). We found nearly identical IncX3-blaOXA-181 plasmids among 11 STs from 12 countries. NDM-5 was frequent in Egypt, Thailand (linked with ST410-B4/H24RxC and ST167-B subclades), and Vietnam (because of ST448). OXA-48 was common in Turkey (linked with ST11260). Global K. pneumoniae carbapenemases were linked with ST131 C1/H30 subclade and NDM-1 with various STs. The global carbapenemase E. coli population is dominated by diverse STs with different characteristics and varied geographic distributions, requiring ongoing genomic surveillance. | en_US |
| dc.description.department | Medical Microbiology | en_US |
| dc.description.librarian | am2023 | en_US |
| dc.description.sponsorship | The Joint Programming Initiative on Antimicrobial Resistance–Canadian Institute Health Research program and the US National Institutes of Health. | en_US |
| dc.description.uri | http://wwwnc.cdc.gov/eid | en_US |
| dc.identifier.citation | Peirano, G., Chen, L., Nobrega, D. et al. 2022, 'Genomic epidemiology of global carbapenemase-producing escherichia coli, 2015–2017', Emerging Infectious Diseases, vol. 28, no. 5, pp. 924-931, doi : 10.3201/eid2805.212535. . | en_US |
| dc.identifier.issn | 1080-6040 (print) | |
| dc.identifier.issn | 1080-6059 (online) | |
| dc.identifier.other | 10.3201/eid2805.212535 | |
| dc.identifier.uri | http://hdl.handle.net/2263/91048 | |
| dc.language.iso | en | en_US |
| dc.publisher | Centers for Disease Control and Prevention | en_US |
| dc.rights | © 2022, Centers for Disease Control and Prevention (CDC). All rights reserved. | en_US |
| dc.subject | Surveillance | en_US |
| dc.subject | Carbapenemases | en_US |
| dc.subject | Molecular epidemiology | en_US |
| dc.subject | Escherichia coli | en_US |
| dc.subject | Bacteria | en_US |
| dc.subject | Whole-genome sequencing (WGS) | en_US |
| dc.subject | Antimicrobial resistance (AMR) | en_US |
| dc.title | Genomic epidemiology of global carbapenemase-producing Escherichia coli, 2015–2017 | en_US |
| dc.type | Article | en_US |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description:
